MedTrace Logo

Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab

NCT01156168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 363

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in tissue samples from patients with breast cancer treated with bevacizumab.

Conditions

Interventions

GENETIC

DNA analysis

GENETIC

gene expression analysis

GENETIC

polymorphism analysis

GENETIC

protein expression analysis

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Bryan P. Schneider, MD · Indiana University Melvin and Bren Simon Cancer Center

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-05
Primary Completion
2011-09-08
Completion
2011-09-08

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01156168 on ClinicalTrials.gov